Literature DB >> 7354134

Direct radioimmunoassay of nuclear 3,5,3' triiodothyronine in rat anterior pituitary.

P R Larsen, S Z Bavli, M Castonguay, R Jove.   

Abstract

Previous tracer studies have suggested that 5'-monodeiodination of l-thyroxine (T(4)) in anterior pituitary may contribute a substantial portion of specifically bound nuclear 3,5,3' l-triiodothyronine (T(3)) in this tissue in rats. To evaluate this possibility, a radioimmunoassay for nuclear T(3) in individual anterior pituitaries was developed. Animals received [(125)I]T(3) 60 min before removal of the anterior pituitary and isolation of the nuclei by differential centrifugation. This allowed calculation of the nuclear:serum T(3) ratio and comparison of expected with measured T(3). T(3) was extracted in ethanol, dried, and reconstituted in assay buffer. In untreated hypothyroid rats, anterior pituitary nuclear T(3) was 0.18 +/- 0.06 pg/mug DNA which was 0.13 pg/mug DNA greater than expected from the serum T(3) concentration and the pituitary nuclear:serum [(125)I]T(3) ratio. In 10 hypothyroid rats given a single bolus of 400 ng T(3)/100 g body wt., the nuclear T(3) by radioimmunoassay was 1.0 +/- 0.06 pg/mug DNA, whereas that expected from the T(3) specific activity calculations was 0.85 pg/mug DNA (P < 0.025). Serum T(4) concentrations in these rats were < 0.25 mug/dl but the nuclear T(3) derived from as little as 0.2 mug/dl T(4) could explain a large portion of these small discrepancies between observed and measured nuclear T(3). In 29 normal rats, anterior pituitary nuclear T(3) was 0.63+/-0.04 pg/mug DNA, whereas that expected from the serum T(3) concentration (55+/-2 ng/dl) was 0.23+/-0.02 pg/mug DNA (P < 0.001). Total pituitary T(3) based on this measurement was 92+/-6 pg. Because the maximal nuclear binding capacity for T(3) in rat anterior pituitary is 0.77 pg/mug DNA, these results suggest there is 82% occupancy of these nuclear receptors. The requirement for normal serum concentrations of both T(4) and T(3) to achieve normal nuclear T(3) saturation in anterior pituitary is in marked contrast to the situation in liver, kidney, and heart muscle which appear to require only a normal serum T(3). As a consequence, the anterior pituitary can monitor both serum T(4) and T(3) and respond appropriately to changes in their concentrations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7354134      PMCID: PMC371409          DOI: 10.1172/JCI109713

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  A practical method for plasma albumin turnover studies.

Authors:  J D PEARSON; N VEALL; H VETTER
Journal:  Strahlentherapie       Date:  1958

2.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

3.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

4.  Triiodothyronine binding in rat anterior pituitary, posterior pituitary, median eminence and brain.

Authors:  A Gordon; O Spira
Journal:  Endocrinology       Date:  1975-06       Impact factor: 4.736

5.  Relationship between the accumulation of pituitary growth hormone and nuclear occupancy by triiodothyronine in the rat.

Authors:  P Coulombe; H L Schwartz; J H Oppenheimer
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

6.  Peripheral metabolism of homologous thyrotropin in euthyroid and hypothyroid rats: acute effects of thyrotropin-releasing hormone, triiodothyronine, and thyroxine.

Authors:  J E Silva; P R Larsen
Journal:  Endocrinology       Date:  1978-06       Impact factor: 4.736

7.  Physiological and pharmacological influences on thyroxine to 3,5,3'-triiodothyronine conversion and nuclear 3,5,3'-triiodothyronine binding in rat anterior pituitary.

Authors:  R G Cheron; M M Kaplan; P R Larsen
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

8.  Isolation of labeled triiodothyronine from serum using affinity chromatography: application to the extimation of the peripheral T4 to T3 conversion in rats.

Authors:  C J Zimmerman; M Izumi; P R Larsen
Journal:  Metabolism       Date:  1978-03       Impact factor: 8.694

9.  Inhibition of intrapituitary thyroxine to 3.5.3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats.

Authors:  P R Larsen; T E Dick; B P Markovitz; M M Kaplan; T G Gard
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Limited binding capacity sites for L-triiodothyronine in rat liver nuclei. Nuclear-cytoplasmic interrelation, binding constants, and cross-reactivity with L-thyroxine.

Authors:  J H Oppenheimer; H L Schwartz; D Koerner; M I Surks
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

View more
  4 in total

1.  Comparative study of pituitary-thyroid hormone economy in fasting and hypothyroid rats.

Authors:  D L St Germain; V A Galton
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

2.  The selective loss of the type 2 iodothyronine deiodinase in mouse thyrotrophs increases basal TSH but blunts the thyrotropin response to hypothyroidism.

Authors:  Cristina Luongo; Cecilia Martin; Kristen Vella; Alessandro Marsili; Raffaele Ambrosio; Monica Dentice; John W Harney; Domenico Salvatore; Ann Marie Zavacki; P Reed Larsen
Journal:  Endocrinology       Date:  2014-12-02       Impact factor: 4.736

3.  Sources and quantity of 3,5,3'-triiodothyronine in several tissues of the rat.

Authors:  J van Doorn; D van der Heide; F Roelfsema
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

4.  Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis.

Authors:  Marisa Eisenberg; Mary Samuels; Joseph J DiStefano
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.